UNSPSC 51433704: Pelanserin

This classification denotes a serotonin antagonist with the molecular formula C21H24N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6SNR96E409, chemically known as 2,4(1h,3h)-quinazolinedione, 3-(3-(4-phenyl-1-piperazinyl)propyl)- but generally known as pelanserin, which bears US NIH Compound Identifier 65435. European Medicines Agency schedules Pelanserin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09648MIG.

UNSPSC 51433704 Pelanserin is a Commodity code covering pharmaceutical products procured by state and local public health agencies, emergency medical services, and coordinated purchasing alliances for use in clinical settings, emergency response, and health benefit programs. State and local governments are buying Advanced Life Support medications, generic multi-source pharmaceuticals, and over-the-counter products through a mix of direct municipal procurement, state pharmacy benefit initiatives, and cooperative purchasing vehicles. The City of Tampa Fire Rescue, Texas Health and Human Services Commission, and Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) represent the range of buying entities—from individual municipal departments to state-level health agencies to multi-state cooperative purchasing consortia. Solicitations require vendors to meet FDA compliance, current Good Manufacturing Practices (cGMP), Drug Supply Chain Security Act (DSCSA) certification, OSHA Hazard Communication Standards for Safety Data Sheets, and accessibility requirements including WCAG 2.2 Level AA conformance. Contracts typically include firm pricing with delivery windows of ten days or less, minimum shelf-life guarantees of six months to nine months from acceptance, warranty periods of one year, and performance penalties ranging from $200 to $1,500 per violation for late reporting or missed onboarding.

Recent activity spans Florida, Texas, and Minnesota. The City of Tampa issued an IFB (Bid No. 26-P-00188) due April 8, 2026, for Advanced Life Support Medications including Labetalol HCI, Epinephrine, Adenosine, and Diltiazem vials for Tampa Fire Rescue, with an estimated contract value of $40,000 and a Small Local Business Enterprise (SLBE) sheltered market designation offering a 5 percent bid discount not to exceed $10,000. The Texas Health and Human Services Commission posted an RFI (HHS0017013) on April 3, 2026, seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program to establish direct relationships between state pharmacy benefit programs and pharmaceutical manufacturers outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Department of Administration issued an RFP through MMCAP (S1070000015802) due March 26, 2026, for generic multi-source pharmaceuticals and OTC products to be distributed across Minnesota, Oregon, and other participating state and local facilities, with awarded vendors effective July 1, 2026, and evaluation weighted 75 percent on price competitiveness, 10 percent on fixed pricing terms, and 5 percent each on administrative fee compliance, EDI capability, and format requirements.